Precision medicine can be considered a “hot topic” in clinical research and some even advocate that it will revolutionise how we approach healthcare in the coming decades. The main idea behind precision medicine is that we tailor treatments to an individual, after measuring certain biological, usually molecular, markers. This approach has achieved some successes in the specialised fields, such as oncology and rheumatology, but much less in primary care. But what makes precision medicine so new? And don’t we already do some form of precision medicine in primary care already? Most precision medicine approaches are based on genomic, proteomic and metabolomic biomarkers. One of the biggest issues with these types of data is that they are too complex for any clinician to interpret. Currently, we are generating these datasets much faster than we can analyse or interpret them, let alone apply them into some kind of clinical setting. My presentation will focus on type 2 diabetes and cardiovascular disease. I will give an overview of where we stand and what we need in the next decade to achieve precision medicine in primary care.